Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development.
about
Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputumIncrease in markers of airway inflammation after ozone exposure can be observed also in stable treated asthmatics with minimal functional response to ozone.Effect of acute ozone induced airway inflammation on human sympathetic nerve traffic: a randomized, placebo controlled, crossover studyEvaluating potential response-modifying factors for associations between ozone and health outcomes: a weight-of-evidence approach.Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development.SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humansEfficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers.The role of oxidative stress and innate immunity in O(3) and endotoxin-induced human allergic airway disease.Challenge models to assess new therapies in chronic obstructive pulmonary disease.Ozone oil promotes wound healing by increasing the migration of fibroblasts via PI3K/Akt/mTOR signaling pathway.Peroxisome proliferator-activated receptor-γ in induced sputum is correlated with MMP-9/TIMP-1 imbalance and formation of emphysema in COPD patients.AMPK activation by peri-sciatic nerve administration of ozone attenuates CCI-induced neuropathic pain in rats.ERK1/2 and p38 regulate inter-individual variability in ozone-mediated IL-8 gene expression in primary human bronchial epithelial cells.Ozone exposure enhances mast-cell inflammation in asthmatic airways despite inhaled corticosteroid therapy
P2860
Q28484224-285AFADF-3EED-401A-BE09-BCE9357534D1Q33634538-970B3D58-B6A2-483E-A9C2-6170ED98031EQ33873634-F71C060E-E234-4BCA-9056-D70D31759770Q34435379-C27241A2-DD21-4648-A1B2-697DA0D86699Q34640736-2CFB3A55-E8C7-4931-9C6B-A77E1827E7DCQ35183636-F01CFF60-DE58-4381-913A-F19531ECCF7BQ35743384-C529C863-B1E5-4AD5-9BBD-B26D046CAF43Q36725405-83846FF4-BBEF-4515-9D16-AD97771EAD9CQ37891127-D62551F5-2B2A-4268-BD2F-187A35408822Q38051306-33183905-CC08-40A9-B82B-0BB978DFCD16Q40070063-558D4951-626E-4ECB-A91C-16AD7886286CQ47101352-390C1E35-2E5C-4155-AB82-9EAB78FC7802Q51390386-C3A09A58-6E63-4FD5-AA48-E996B9E18870Q55491334-0C01BB01-3CA1-4D4C-8EFB-069024B82278Q57269364-DC7AEEE7-B3D0-43A2-B214-A66ABA8A30B3
P2860
Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Validation of the human ozone ...... ry drugs in early development.
@en
Validation of the human ozone ...... ry drugs in early development.
@nl
type
label
Validation of the human ozone ...... ry drugs in early development.
@en
Validation of the human ozone ...... ry drugs in early development.
@nl
prefLabel
Validation of the human ozone ...... ry drugs in early development.
@en
Validation of the human ozone ...... ry drugs in early development.
@nl
P2093
P2860
P356
P1476
Validation of the human ozone ...... ry drugs in early development.
@en
P2093
Anthony Gibson
Frank Kanniess
Helgo Magnussen
Kai Richter
Kathy J Simpson
Rudolf A Jörres
Rupert S J Vessey
Stanislawa Janicki
P2860
P304
P356
10.1177/0091270004273527
P577
2005-05-01T00:00:00Z